logo

Cti Biopharma Corp. (CTIC)



Trade CTIC now with
  Date
  Headline
6/1/2020 7:02:42 AM CTI BioPharma Enrolls 1st Patient In Phase 3 PRE-VENT Trial Of Pacritinib In Hospitalized Patients With Severe COVID-19
5/7/2020 4:16:42 PM CTI BioPharma Q1 Loss/share $0.20 Vs. Loss $0.19 Year Ago
4/27/2020 7:02:08 AM CTI BioPharma Initiates PRE-VENT Phase 3 Study Evaluating Pacritinib In Hospitalized Patients With Severe COVID-19
3/12/2020 4:06:51 PM CTI BioPharma Q4 Loss/share $0.14 Vs. Profit $0.01 Year Ago
2/14/2020 7:04:52 AM CTI BioPharma Commences Rights Offering To Raise Gross Proceeds Of About $60.0 Mln
2/3/2020 7:02:17 AM CTI BioPharma Intends To Raise $60 Mln Through Fully Backstopped Rights Offering
2/3/2020 7:01:52 AM CTI Establishes Accelerated Approval Pathway For Pacritinib In Myelofibrosis Patients With Severe Thrombocytopenia
11/4/2019 4:15:14 PM CTI BioPharma Q3 Loss/share $0.17 Vs. Loss $0.26 Year Ago
10/1/2019 7:02:16 AM CTI BioPharma Begins Patient Enrollment In PACIFICA Pivotal Phase 3 Trial Of Pacritinib
8/1/2019 4:14:45 PM CTI BioPharma Q2 Loss/share $0.19 Vs. Loss $0.20 Year Ago
7/18/2019 7:04:25 AM CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With FDA Regarding Pacritinib For Myelofibrosis